Respiratory Syncytial Contagion – A Narrative Review on Its History, Pathophysiology, Diagnosis, Treatment and Prevention
Abstract
Respiratory syncytial contagion (RSC) is a common respiratory contagion that generally leads to mild, cold-like symptoms. However, it can be severe, especially in babies and aged grown-ups who may face hospitalisation. A comprehensive review of RSC is important as it covers various aspects like its history, mechanism, causes, symptoms, duration, treatment, incubation, complications, and prevention, furnishing a thorough understanding of this viral infection that affects the respiratory system. This review explores the crucial aspects of RSC, including its transmission, symptoms, and implicit complications. RSC is highly contagious and spreads through respiratory droplets when an infected person coughs or sneezes. Common symptoms include coughing, sneezing, fever, and difficulty breathing. High-risk premature babies, individuals with weakened vulnerable systems, and senior citizens are at advanced threat for severe RSC infections. Preventative measures
include good hygiene practices, similar to frequent hand washing, and vaccination in certain high-threat populations. Palivizumab, a monoclonal antibody, may also be administered to help severe RSC in certain babies. There is no specific antiviral treatment for RSC, but preventive care is essential. This may include oxygen remedy, hydration, and in severe cases, hospitalisation.
How to cite this article:
Rajappa C M, Moorthi G S, Sivaji R, Palanivel
P, Singh P M, Vanan T A . Respiratory Syncytial
Contagion – A Narrative Review on Its History,
Pathophysiology, Diagnosis, Treatment and
Prevention J Commun Dis. 2024;56(2):80-89.
DOI: https://doi.org/10.24321/0019.5138.202436
References
Pinquier D, Crépey P, Tissières P, Vabret A, Roze JC, Dubos F, Cahn-Sellem F, Javouhey E, Cohen R, Weil-Olivier C. Preventing respiratory syncytial virus in children in France: a narrative review of the importance of a reinforced partnership between parents, healthcare professionals, and public health authorities. Infect Dis Ther. 2023;12(2):317-32. [PubMed] [Google Scholar]
Hall CB. Respiratory syncytial virus: its transmission in the hospital environment. Yale J Biol Med. 1982;55(3- 4):219. [PubMed] [Google Scholar]
Kulkarni H, Smith CM, Lee DD, Hirst RA, Easton AJ, O’Callaghan C. Evidence of respiratory syncytial virus
spread by aerosol. Time to revisit infection control strategies? Am J Respir Crit Care Med. 2016;194(3):308-
[PubMed] [Google Scholar]
Hashem M, Hall CB. Respiratory syncytial virus in healthy adults: the cost of a cold. J Clin Virol. 2003;27(1):14-21. [PubMed] [Google Scholar]
Anderson LJ, Tsou C, Potter C, Keyserling HL, Smith TF, Ananaba G, Bangham CR. Cytokine response to
respiratory syncytial virus stimulation of human peripheral blood mononuclear cells. J Infect Dis. 1994;170(5):1201-8. [PubMed] [Google Scholar]
Bangham CR, Openshaw PJ, Ball LA, King AM, Wertz GW, Askonas BA. Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J Immunol. 1986;137(12):3973-7. [PubMed] [Google Scholar]
Bright H, Turnbull T, Toms GL, Scott R. Comparison of the T helper cell response induced by respiratory
syncytial virus and its fusion protein in BALB/c mice. Vaccine. 1995;13(10):915-22. [PubMed] [Google
Scholar]
Chanock RM, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA): I. Isolation, properties and characterization. Am J Hyg. 1957;66(3):281-90.
[PubMed] [Google Scholar]
Chanock RM, Parrott RH, Connors M, Collins PL, Murphy BR. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatrics. 1992;90(1 Pt 2):137-43. [PubMed] [Google Scholar]
Falsey AR, Cunningham CK, Barker WH, Kouides RW, Yuen JB, Menegus M, Weiner LB, Bonville CA, Betts RF. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis. 1995;172(2):389-
[PubMed] [Google Scholar]
Fouillard L, Mouthon L, Laporte JP, Isnard F, Stachowiak J, Aoudijhane M, Lucet JC, Wolf M, Bricourt F, Douay
L. Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. Bone Marrow Transplant. 1992;9(2):97-100. [PubMed] [Google Scholar]
Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial
virus. Am J Dis Child. 1986;140(6):543-6. [PubMed] [Google Scholar]
Graham BS, Bunton LA, Rowland J, Wright PF, Karzon DT. Respiratory syncytial virus infection in anti-mu-
treated mice. J Virol. 1991;65(9):4936-42. [PubMed] [Google Scholar]
Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol. 1993;151(4):2032-40. [PubMed] [Google Scholar]
Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, Tristam DA, Siber GR, Prince GA, Raden MV, Hemming VG; Respiratory Syncytial Virus Immune Globulin Study Group. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329(21):1524-30. [PubMed] [Google Scholar]
Hall CB. The nosocomial spread of respiratory syncytial viral infections. Annu Rev Med. 1983;34:311-9.
[PubMed] [Google Scholar]
Hall CB, Kopelman AE, Douglas RG Jr, Geiman JM, Meagher MP. Neonatal respiratory syncytial virus
infection. N Engl J Med. 1979;300(8):393-6. [PubMed] [Google Scholar]
Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, Eyck LG, Hall WJ. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med. 1983;308(24):1443-7. [PubMed] [Google Scholar]
Hall CB, Powell KR, Macdonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986;315(2):77-80. [PubMed] [Google Scholar]
Hall CB, Walsh EE, Schnabel KC, Long CE, McConnochie KM, Hildreth SW, Anderson LJ. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalised and ambulatory children. J Infect Dis. 1990;162(6):1283-90. [PubMed] [Google Scholar]
McConnochie KM, Hall CB, Walsh EE, Roghmann KJ. Variation in severity of respiratory syncytial virus infections with subtype. J Pediatr. 1990;117(1 Pt 1):52- 62. [PubMed] [Google Scholar]
Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, Rodriguez WJ, Chanock RM. Dissociation
between serum neutralising and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol. 1986;24(2):197-202. [PubMed] [Google Scholar]
Navas L, Wang E, de Carvalho V, Robinson J; Pediatric Investigators Collaborative Network on Infections in Canada. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalised population of Canadian children. J Pediatr. 1992;121(3):348-54. [PubMed] [Google Scholar]
Oien NL, Brideau RJ, Thomsen DR, Homa FL, Wathen MW. Vaccination with a heterologous respiratory
syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity. Vaccines. 1993;11(10):1040-8. [PubMed] [Google Scholar]
Paradiso PR, Hildreth SW, Hogerman DA, Speelman DJ, Lewin EB, Oren J, Smith DH. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J. 1994;13(9):792-8. [PubMed] [Google Scholar]
Springer C, Bar-Yishay E, Uwayyed K, Avital A, Vilzoni D, Godfrey S. Corticosteroids do not affect the clinical or physiological status of infants with bronchiolitis. Pediatr Pulmonol. 1990;9(3):181-5. [Google Scholar]
Takimoto CH, Cram DL, Root RK. Respiratory syncytial virus infections on an adult medical ward. Arch Intern Med. 1991;151(4):706-8. [PubMed] [Google Scholar]
Hruska JF, Bernstein JM, Douglas Jr RG, Hall CB. Effects of ribavirin on respiratory syncytial virus in vitro.
Antimicrob Agents Chemother. 1980;17(5):770-5. [PubMed] [Google Scholar]
Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. Arch Pediatr Adolesc Med. 1996;150(9):942-7. [PubMed] [Google Scholar]
Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev. 2007;1:CD000181. [Google Scholar]
Toms GL. Respiratory syncytial virus: virology, diagnosis, and vaccination. Lung. 1990;168:388-95. [PubMed] [Google Scholar]
Toms GL. Respiratory syncytial virus—how soon will we have a vaccine? Arch Dis Child. 1995;72(1):1-3. [PubMed] [Google Scholar]
Toms GL, Quinn R, Robinson JW. Undetectable IgE responses after respiratory syncytial virus infection.
Arch Dis Child. 1996;74(2):126-30. [PubMed] [Google Scholar]
Copyright (c) 2024 Journal of Communicable Diseases (E-ISSN: 2581-351X & P-ISSN: 0019-5138)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
